General Information of Drug (ID: DMEOBNJ)

Drug Name
3,6-Diphenyl-1-oxa-7-aza-spiro[4.5]decane Drug Info
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
44324916
TTD Drug ID
DMEOBNJ

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Aprepitant DM053KT Depression 6A70-6A7Z Approved [2]
Selegiline DM6034S Major depressive disorder 6A70.3 Approved [3]
Rolapitant DM8XP26 Chemotherapy-induced nausea MD90 Approved [4]
Netupitant DMEKAYI Chemotherapy-induced nausea MD90 Phase 3 [4]
Serlopitant DM5VH6U Prurigo nodularis EC91.0 Phase 3 [5]
LY-686017 DM7WORZ Atopic dermatitis EA80 Phase 3 [6]
Elinzanetant DMC6EFI Hot flushes GA30 Phase 3 [7]
CP-122721 DMSWLM5 Major depressive disorder 6A70.3 Phase 2 [8]
FR139317 DMEL5SV Hypertension BA00-BA04 Phase 2 [3]
VOFOPITANT HYDROCHLORIDE DMQMYP5 Vomiting MD90 Phase 2 [9]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Substance-P receptor (TACR1) TTZPO1L NK1R_HUMAN Inhibitor [1]

References

1 Spirocyclic NK(1) antagonists II: [4.5]-spiroethers. Bioorg Med Chem Lett. 2002 Oct 7;12(19):2719-22.
2 Potent, brain-penetrant, hydroisoindoline-based human neurokinin-1 receptor antagonists. J Med Chem. 2009 May 14;52(9):3039-46.
3 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
4 Netupitant and palonosetron trigger NK1 receptor internalization in NG108-15 cells. Exp Brain Res. 2014 Aug;232(8):2637-44.
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6 Stress-related neuropeptides and alcoholism: CRH, NPY and beyond. Alcohol. 2009 November; 43(7): 491-498.
7 Elinzanetant (NT-814), a Neurokinin 1,3 Receptor Antagonist, Reduces Estradiol and Progesterone in Healthy Women. J Clin Endocrinol Metab. 2021 Jul 13;106(8):e3221-e3234.
8 A review of drug options in age-related macular degeneration therapy and potential new agents. Expert Opin Pharmacother. 2006 Dec;7(17):2355-68.
9 Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenicchemotherapy: a randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009 Jun;10(6):549-58.